Trade Summary

4 days ago, Regnante Keith, serving as CFO at Keros Therapeutics, Inc. (KROS), sold 4,739 shares at $16.35 per share, for a total transaction value of $77,483.00. Following this transaction, Regnante Keith now holds 39,261 shares of KROS.

This sale represents a 11.00% decrease in Regnante Keith's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, February 18, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 20, 2026, 2 days after the trade was made.

Keros Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.